Table 1 Baseline characteristics of the study population
Characteristics | Value (N = 18) |
|---|---|
Age, years, median (IQR) | 68 (59–73) |
Female, N (%) | 16 (88.9) |
Body mass index, median (IQR) | 20.6 (16.2–21.3) |
RA duration, years, median (IQR) | 14.8 (8.6–19.5) |
Rheumatoid factor positive, N (%) | 14 (77.8) |
Anti-CCP antibody positive, N (%) | 9 (50.0) |
RA-associated interstitial lung disease, N (%) | 8 (44.4) |
Conventional synthetic DMARDs before NTM-PD diagnosis | |
Methotrexate | 17 (94.4) |
Hydroxychloroquine | 12 (66.7) |
Sulfasalazine | 11 (61.1) |
Leflunomide | 5 (27.8) |
Tacrolimus | 2 (11.1) |
Biologics used before NTM-PD diagnosis | |
Infliximab | 1 (5.6) |
Adalimumab | 2 (11.1) |
Tocilizumab | 1 (5.6) |
AFB smear positivity, N (%) | 4 (22.2) |
Mycobacterial species, N (%) | |
M. avium | 10 (55.6) |
M. intracellulare | 6 (33.3) |
M. abscessus subspecies abscessus | 1 (5.6) |
M. abscessus subspecies massiliense | 1 (5.6) |
Presence of cavity, N (%) | 6 (33.3) |